The University of Hong Kong, Queen Mary Hospital
Welcome,         Profile    Billing    Logout  
 14 Trials 
14 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hung, Ivan FN
NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

Recruiting
3
4000
RoW
Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP
The University of Hong Kong
Influenza
09/22
03/23
NCT05382871: Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above

Active, not recruiting
3
1804
RoW
BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), COVID-19 Vaccine (Vero Cell), Inactivated
China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd., Wuhan Institute of Biological Products Co., Ltd, The University of Hong Kong
COVID-19
07/23
03/24
NCT04900415: Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction

Recruiting
2
25
RoW
Vitamin A, Electronic portable aromatic rehabilitation (EPAR) diffuser
Ivan FN Hung MD, Pamela Youde Nethersole Eastern Hospital
Coronavirus Disease 2019
03/21
06/21
NCT04465695: Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

Recruiting
2
81
RoW
Interferon beta-1b, Clofazimine
The University of Hong Kong
COVID-19
06/21
09/21
NCT04647695: IFN-beta 1b and Remdesivir for COVID19

Recruiting
2
100
RoW
Interferon beta-1b, Remdesivir
The University of Hong Kong
Covid19
07/21
09/21
NCT04494399: IFN Beta-1b and Ribavirin for Covid-19

Recruiting
2
96
RoW
Interferon beta-1b, Ribavirin
The University of Hong Kong, Hospital Authority, Hong Kong
Covid19
07/22
08/22
NCT05736913: Intradermal COVID-19 Vaccination in the Immunocompromised

Recruiting
2
130
RoW
ID BNT162b2 vaccine, IM BNT162b2 vaccine
The University of Hong Kong
COVID-19
03/23
06/23
NCT05200741: To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2

Recruiting
2
150
RoW
DelNS1-2019-nCoV-RBD-OPT1, Matching placebo
The University of Hong Kong
Covid19
02/24
02/24
NCT05102643: A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19

Recruiting
1
30
RoW
SARS-CoV-2 DNA Vaccine, Matching placebo
The University of Hong Kong, Immuno Cure 3 Limited
Covid19
06/22
12/22
NCT04809389: A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19

Active, not recruiting
1
115
RoW
DelNS1-nCoV-RBD LAIV, Matching placebo
The University of Hong Kong
Covid19
09/22
09/22
To, Kelvin
NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

Recruiting
3
4000
RoW
Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP
The University of Hong Kong
Influenza
09/22
03/23
NCT04494399: IFN Beta-1b and Ribavirin for Covid-19

Recruiting
2
96
RoW
Interferon beta-1b, Ribavirin
The University of Hong Kong, Hospital Authority, Hong Kong
Covid19
07/22
08/22
Zhang, Anna
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Completed
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
10/24
10/24
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Recruiting
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
06/28
10/28
Chan, Kwok-Hung
No trials found
On, LAM Ka
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hung, Ivan FN
NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

Recruiting
3
4000
RoW
Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP
The University of Hong Kong
Influenza
09/22
03/23
NCT05382871: Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above

Active, not recruiting
3
1804
RoW
BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), COVID-19 Vaccine (Vero Cell), Inactivated
China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd., Wuhan Institute of Biological Products Co., Ltd, The University of Hong Kong
COVID-19
07/23
03/24
NCT04900415: Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction

Recruiting
2
25
RoW
Vitamin A, Electronic portable aromatic rehabilitation (EPAR) diffuser
Ivan FN Hung MD, Pamela Youde Nethersole Eastern Hospital
Coronavirus Disease 2019
03/21
06/21
NCT04465695: Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19

Recruiting
2
81
RoW
Interferon beta-1b, Clofazimine
The University of Hong Kong
COVID-19
06/21
09/21
NCT04647695: IFN-beta 1b and Remdesivir for COVID19

Recruiting
2
100
RoW
Interferon beta-1b, Remdesivir
The University of Hong Kong
Covid19
07/21
09/21
NCT04494399: IFN Beta-1b and Ribavirin for Covid-19

Recruiting
2
96
RoW
Interferon beta-1b, Ribavirin
The University of Hong Kong, Hospital Authority, Hong Kong
Covid19
07/22
08/22
NCT05736913: Intradermal COVID-19 Vaccination in the Immunocompromised

Recruiting
2
130
RoW
ID BNT162b2 vaccine, IM BNT162b2 vaccine
The University of Hong Kong
COVID-19
03/23
06/23
NCT05200741: To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2

Recruiting
2
150
RoW
DelNS1-2019-nCoV-RBD-OPT1, Matching placebo
The University of Hong Kong
Covid19
02/24
02/24
NCT05102643: A Study to Evaluate Safety & Immunogenicity of SARS-CoV-2 DNA Vaccine Delivered Intramuscularly Followed by Electroporation for COVID-19

Recruiting
1
30
RoW
SARS-CoV-2 DNA Vaccine, Matching placebo
The University of Hong Kong, Immuno Cure 3 Limited
Covid19
06/22
12/22
NCT04809389: A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19

Active, not recruiting
1
115
RoW
DelNS1-nCoV-RBD LAIV, Matching placebo
The University of Hong Kong
Covid19
09/22
09/22
To, Kelvin
NCT04143451: Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

Recruiting
3
4000
RoW
Vaxigrip tetra, Fluzone high-dose, Aldara 5% Topical Cream, Aqueous cream BP
The University of Hong Kong
Influenza
09/22
03/23
NCT04494399: IFN Beta-1b and Ribavirin for Covid-19

Recruiting
2
96
RoW
Interferon beta-1b, Ribavirin
The University of Hong Kong, Hospital Authority, Hong Kong
Covid19
07/22
08/22
Zhang, Anna
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Completed
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
10/24
10/24
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Recruiting
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
06/28
10/28
Chan, Kwok-Hung
No trials found
On, LAM Ka
No trials found

Download Options